Applications of Biosensors in Bladder Cancer

References

• Jubber, I.; Ong, S.; Bukavina, L.; Black, P. C.; Compérat, E.; Kamat, A. M.; Kiemeney, L.; Lawrentschuk, N.; Lerner, S. P.; Meeks, J. J.; et al. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur. Urol. 2023, 84, 176–190. DOI: 10.1016/j.eururo.2023.03.029.
   PubMed Web of Science ®Google Scholar
• Humphrey, P. A.; Moch, H.; Cubilla, A. L.; Ulbright, T. M.; Reuter, V. E. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur. Urol. 2016, 70, 106–119. DOI: 10.1016/j.eururo.2016.02.028.
   PubMed Web of Science ®Google Scholar
• Compérat, E.; Amin, M. B.; Cathomas, R.; Choudhury, A.; De Santis, M.; Kamat, A.; Stenzl, A.; Thoeny, H. C.; Witjes, J. A. Current Best Practice for Bladder Cancer: A Narrative Review of Diagnostics and Treatments. Lancet 2022, 400, 1712–1721. DOI: 10.1016/S0140-6736(22)01188-6.
   PubMed Web of Science ®Google Scholar
• Lenis, A. T.; Lec, P. M.; Chamie, K.; Mshs, M. D. Bladder Cancer: A Review. JAMA. 2020, 324, 1980–1991. DOI: 10.1001/jama.2020.17598.
   PubMed Web of Science ®Google Scholar
• Kamat, A. M.; Hahn, N. M.; Efstathiou, J. A.; Lerner, S. P.; Malmström, P. U.; Choi, W.; Guo, C. C.; Lotan, Y.; Kassouf, W. Bladder Cancer. Lancet. 2016, 388, 2796–2810. DOI: 10.1016/S0140-6736(16)30512-8.
   PubMed Web of Science ®Google Scholar
• Alfred Witjes, J.; Max Bruins, H.; Carrión, A.; Cathomas, R.; Compérat, E.; Efstathiou, J. A.; Fietkau, R.; Gakis, G.; Lorch, A.; Martini, A.; et al. European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur. Urol. 2024, 85, 17–31. DOI: 10.1016/j.eururo.2023.08.016.
   PubMed Web of Science ®Google Scholar
• Kozikowski, M.; Suarez-Ibarrola, R.; Osiecki, R.; Bilski, K.; Gratzke, C.; Shariat, S. F.; Miernik, A.; Dobruch, J. Role of Radiomics in the Prediction of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Eur. Urol. Focus. 2022, 8, 728–738. DOI: 10.1016/j.euf.2021.05.005.
   PubMedGoogle Scholar
• Babjuk, M.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E. M.; Dominguez Escrig, J. L.; Gontero, P.; Liedberg, F.; Masson-Lecomte, A.; Mostafid, A. H.; et al. European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur. Urol. 2022, 81, 75–94. DOI: 10.1016/j.eururo.2021.08.010.
   PubMed Web of Science ®Google Scholar
• Crocetto, F.; Barone, B.; Ferro, M.; Busetto, G. M.; La Civita, E.; Buonerba, C.; Di Lorenzo, G.; Terracciano, D.; Schalken, J. A. Liquid Biopsy in Bladder Cancer: State of the Art and Future Perspectives. Crit. Rev. Oncol. Hematol. 2022, 170, 103577. DOI: 10.1016/j.critrevonc.2022.103577.
   PubMed Web of Science ®Google Scholar
• Zhao, J.; Li, J.; Zhang, R. Off the Fog to Find the Optimal Choice: Research Advances in Biomarkers for Early Diagnosis and Recurrence Monitoring of Bladder Cancer. Biochim. Biophys. Acta. Rev. Cancer. 2023, 1878, 188926. DOI: 10.1016/j.bbcan.2023.188926.
   PubMed Web of Science ®Google Scholar
• Jayanthi, V.; Das, A. B.; Saxena, U. Recent Advances in Biosensor Development for the Detection of Cancer Biomarkers. Biosens. Bioelectron. 2017, 91, 15–23. DOI: 10.1016/j.bios.2016.12.014.
   PubMed Web of Science ®Google Scholar
• Son, M. H.; Park, S. W.; Sagong, H. Y.; Jung, Y. K. Recent Advances in Electrochemical and Optical Biosensors for Cancer Biomarker Detection. BioChip J. 2023, 17, 44–67. DOI: 10.1007/s13206-022-00089-6.
   Web of Science ®Google Scholar
• Chikkaveeraiah, B. V.; Bhirde, A. A.; Morgan, N. Y.; Eden, H. S.; Chen, X. Electrochemical Immunosensors for Detection of Cancer Protein Biomarkers. ACS Nano. 2012, 6, 6546–6561. DOI: 10.1021/nn3023969.
   PubMed Web of Science ®Google Scholar
• Azab, M. Y.; Hameed, M. F. O.; Obayya, S. S. A. Overview of Optical Biosensors for Early Cancer Detection: Fundamentals, Applications and Future Perspectives. Biology. (Basel). 2023, 12,232. DOI: 10.3390/biology12020232.
   PubMedGoogle Scholar
• Yang, Y.; Huang, Q.; Xiao, Z.; Liu, M.; Zhu, Y.; Chen, Q.; Li, Y.; Ai, K. Nanomaterial-Based Biosensor Developing as a Route toward in Vitro Diagnosis of Early Ovarian Cancer. Mater. Today. Bio. 2022, 13, 100218. DOI: 10.1016/j.mtbio.2022.100218.
   PubMedGoogle Scholar
• Liu, M.; Xiang, Y. T.; Yang, Y. Q.; Long, X. Y.; Xiao, Z. X.; Nan, Y. Y.; Jiang, Y. T.; Qiu, Y. G.; Huang, Q.; Ai, K. L. State-of-the-Art Advancements in Liver-on-a-Chip (LOC): Integrated Biosensors for LOC. Biosens. Bioelectron. 2022, 218, 114758. DOI: 10.1016/j.bios.2022.114758.
   PubMed Web of Science ®Google Scholar
• Patel, V. G.; Oh, W. K.; Galsky, M. D. Treatment of Muscle-Invasive and Advanced Bladder Cancer in 2020. CA. Cancer J. Clin. 2020, 70, 404–423. DOI: 10.3322/caac.21631.
   PubMed Web of Science ®Google Scholar
• Lopez-Beltran, A.; Cookson, M. S.; Guercio, B. J.; Cheng, L. Advances in Diagnosis and Treatment of Bladder Cancer. BMJ. 2024, 384, e076743. DOI: 10.1136/bmj-2023-076743.
   PubMedGoogle Scholar
• García-Pardo, M.; Makarem, M.; Li, J. J. N.; Kelly, D.; Leighl, N. B. Integrating Circulating-Free DNA (cfDNA) Analysis into Clinical Practice: Opportunities and Challenges. Br. J. Cancer. 2022, 127, 592–602. DOI: 10.1038/s41416-022-01776-9.
   PubMed Web of Science ®Google Scholar
• Song, P.; Wu, L. R.; Yan, Y. H.; Zhang, J. X.; Chu, T.; Kwong, L. N.; Patel, A. A.; Zhang, D. Y. Limitations and Opportunities of Technologies for the Analysis of Cell-Free DNA in Cancer Diagnostics. Nat. Biomed. Eng. 2022, 6, 232–245. DOI: 10.1038/s41551-021-00837-3.
   PubMed Web of Science ®Google Scholar
• Patel, K. M.; van der Vos, K. E.; Smith, C. G.; Mouliere, F.; Tsui, D.; Morris, J.; Chandrananda, D.; Marass, F.; van den Broek, D.; Neal, D. E.; et al. Association Of Plasma And Urinary Mutant DNA with Clinical Outcomes In Muscle Invasive Bladder Cancer. Sci. Rep. 2017, 7, 5554. DOI: 10.1038/s41598-017-05623-3.
   PubMed Web of Science ®Google Scholar
• Todenhöfer, T.; Struss, W. J.; Seiler, R.; Wyatt, A. W.; Black, P. C. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer. 2018, 4, 19–29. DOI: 10.3233/BLC-170140.
   PubMed Web of Science ®Google Scholar
• Christensen, E.; Birkenkamp-Demtröder, K.; Sethi, H.; Shchegrova, S.; Salari, R.; Nordentoft, I.; Wu, H. T.; Knudsen, M.; Lamy, P.; Lindskrog, S. V.; et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients with Urothelial Bladder Carcinoma. J. Clin. Oncol. 2019, 37, 1547–1557. DOI: 10.1200/JCO.18.02052.
   PubMed Web of Science ®Google Scholar
• Crupi, E.; de Padua, T. C.; Marandino, L.; Raggi, D.; Dyrskjøt, L.; Spiess, P. E.; Sonpavde, G. P.; Kamat, A. M.; Necchi, A. Circulating Tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review. Eur. Urol. Oncol. 2024, 7, 44–52. DOI: 10.1016/j.euo.2023.05.012.
   PubMed Web of Science ®Google Scholar
• Le Goux, C.; Vacher, S.; Schnitzler, A.; Barry Delongchamps, N.; Zerbib, M.; Peyromaure, M.; Sibony, M.; Allory, Y.; Bieche, I.; Damotte, D.; Pignot, G. Assessment of Prognostic Implication of a Panel of Oncogenes in Bladder Cancer and Identification of a 3-Gene Signature Associated with Recurrence and Progression Risk in Non-Muscle-Invasive Bladder Cancer. Sci. Rep. 2020, 10, 16641. DOI: 10.1038/s41598-020-73642-8.
   PubMed Web of Science ®Google Scholar
• Ascione, C. M.; Napolitano, F.; Esposito, D.; Servetto, A.; Belli, S.; Santaniello, A.; Scagliarini, S.; Crocetto, F.; Bianco, R.; Formisano, L. Role of FGFR3 in Bladder Cancer: Treatment Landscape and Future Challenges. Cancer Treat. Rev. 2023, 115, 102530. DOI: 10.1016/j.ctrv.2023.102530.
   PubMed Web of Science ®Google Scholar
• Duffy, M. J.; Synnott, N. C.; McGowan, P. M.; Crown, J.; O'Connor, D.; Gallagher, W. M. p53 as a Target for the Treatment of Cancer. Cancer Treat. Rev. 2014, 40, 1153–1160. DOI: 10.1016/j.ctrv.2014.10.004.
   PubMed Web of Science ®Google Scholar
• Joerger, A. C.; Fersht, A. R. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annu. Rev. Biochem. 2016, 85, 375–404. DOI: 10.1146/annurev-biochem-060815-014710.
   PubMed Web of Science ®Google Scholar
• Matuszczak, M.; Salagierski, M. Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. Int. J. Mol. Sci. 2020, 21, 3360. DOI: 10.3390/ijms21093360.
   PubMed Web of Science ®Google Scholar
• van Rhijn, B. W.; van der Kwast, T. H.; Vis, A. N.; Kirkels, W. J.; Boevé, E. R.; Jöbsis, A. C.; Zwarthoff, E. C. FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma. Cancer Res. 2004, 64, 1911–1914. DOI: 10.1158/0008-5472.can-03-2421.
   PubMed Web of Science ®Google Scholar
• Shin, Y.; Perera, A. P.; Park, M. K. Label-Free DNA Sensor for Detection of Bladder Cancer Biomarkers in Urine. Sens. Actuators, B. 2013, 178, 200–206. DOI: 10.1016/j.snb.2012.12.057.
   Web of Science ®Google Scholar
• Thangsunan, P.; Lal, N.; Tiede, C.; Moul, S.; Robinson, J. I.; Knowles, M. A.; Stockley, P. G.; Beales, P. A.; Tomlinson, D. C.; McPherson, M. J.; Millner, P. A. Affimer-Based Impedimetric Biosensors for Fibroblast Growth Factor Receptor 3 (FGFR3): A Novel Tool for Detection and Surveillance of Recurrent Bladder Cancer. Sens. Actuators, B. 2021, 326, 128829. DOI: 10.1016/j.snb.2020.128829.
   Web of Science ®Google Scholar
• Chen, D. F.; Wu, Y. F. Rapid and Ultrasensitive Electrochemical Detection of TP53 Gene Mutation in Blood: Hybridization with a DNA/Gold-Coated Magnetic Nanoparticle Network. Anal. Sens. 2022, 2. E202200032.DOI: 10.1002/anse.202200032.
   Google Scholar
• Kinde, I.; Munari, E.; Faraj, S. F.; Hruban, R. H.; Schoenberg, M.; Bivalacqua, T.; Allaf, M.; Springer, S.; Wang, Y.; Diaz, L. A. Jr.; et al. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine. Cancer Res. 2013, 73, 7162–7167. DOI: 10.1158/0008-5472.CAN-13-2498.
   PubMed Web of Science ®Google Scholar
• Zvereva, M.; Pisarev, E.; Hosen, I.; Kisil, O.; Matskeplishvili, S.; Kubareva, E.; Kamalov, D.; Tivtikyan, A.; Manel, A.; Vian, E.; et al. Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. Int. J. Mol. Sci. 2020, 21, 6034. DOI: 10.3390/ijms21176034.
   PubMed Web of Science ®Google Scholar
• Hosen, M. I.; Sheikh, M.; Zvereva, M.; Scelo, G.; Forey, N.; Durand, G.; Voegele, C.; Poustchi, H.; Khoshnia, M.; Roshandel, G.; et al. Urinary TERT Promoter Mutations Are Detectable up to 10 Years Prior to Clinical Diagnosis of Bladder Cancer: Evidence from the Golestan Cohort Study. EBioMedicine. 2020, 53, 102643. DOI: 10.1016/j.ebiom.2020.102643.
   PubMed Web of Science ®Google Scholar
• Gourd, E. TERT Mutations in Urine Could Predict Bladder Cancer Recurrence. Lancet. Oncol. 2017, 18, e443. DOI: 10.1016/S1470-2045(17)30538-7.
   PubMed Web of Science ®Google Scholar
• Beukers, W.; van der Keur, K. A.; Kandimalla, R.; Vergouwe, Y.; Steyerberg, E. W.; Boormans, J. L.; Jensen, J. B.; Lorente, J. A.; Real, F. X.; Segersten, U.; et al. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J. Urol. 2017, 197, 1410–1418. DOI: 10.1016/j.juro.2016.12.096.
   PubMed Web of Science ®Google Scholar
• Cai, A.; Yang, L.; Kang, X.; Liu, J.; Wang, F.; Ji, H.; Wang, Q.; Wu, M.; Li, G.; Zhou, X.; et al. Target Recognition– and HCR Amplification–Induced In Situ Electrochemical Signal Probe Synthesis Strategy for Trace ctDNA Analysis. Biosensors (Basel). 2022, 12, 989. DOI: 10.3390/bios12110989.
   PubMedGoogle Scholar
• Chen, D.; Wu, Y.; Hoque, S.; Tilley, R. D.; Gooding, J. J. Rapid and Ultrasensitive Electrochemical Detection of Circulating Tumor DNA by Hybridization on the Network of Gold-Coated Magnetic Nanoparticles. Chem. Sci. 2021, 12, 5196–5201. DOI: 10.1039/d1sc01044a.
   PubMed Web of Science ®Google Scholar
• Li, M.; Luo, N.; Liao, X.; Zou, L. Proximity Hybridization-Regulated CRISPR/Cas12a-Based Dual Signal Amplification Strategy for Sensitive Detection of Circulating Tumor DNA. Talanta. 2023, 257, 124395. DOI: 10.1016/j.talanta.2023.124395.
   PubMed Web of Science ®Google Scholar
• Li, D.; Chen, H.; Fan, K.; Labunov, V.; Lazarouk, S.; Yue, X.; Liu, C.; Yang, X.; Dong, L.; Wang, G. A Supersensitive Silicon Nanowire Array Biosensor for Quantitating Tumor Marker ctDNA. Biosens. Bioelectron. 2021, 181, 113147. DOI: 10.1016/j.bios.2021.113147.
   PubMed Web of Science ®Google Scholar
• Yang, L.; Zhou, X.; Zhang, K.; Liu, J.; Zhao, L.; Cai, A.; Zhao, X.; Wu, L.; Qin, Y. Electrochemiluminescent/Electrochemical Ratiometric Biosensor for Extremely Specific and Ultrasensitive Detection of Circulating Tumor DNA. Sens. Actuators, B. 2023, 382, 133490. DOI: 10.1016/j.snb.2023.133490.
   Web of Science ®Google Scholar
• Ali Syeda, Z.; Langden, S. S. S.; Munkhzul, C.; Lee, M.; Song, S. J. Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci. 2020, 21, 1723. DOI: 10.3390/ijms21051723.
   PubMed Web of Science ®Google Scholar
• Lin, S.; Gregory, R. I. MicroRNA Biogenesis Pathways in Cancer. Nat. Rev. Cancer. 2015, 15, 321–333. DOI: 10.1038/nrc3932.
   PubMed Web of Science ®Google Scholar
• Di Leva, G.; Garofalo, M.; Croce, C. M. MicroRNAs in Cancer. Annu. Rev. Pathol. 2014, 9, 287–314. DOI: 10.1146/annurev-pathol-012513-104715.
   PubMed Web of Science ®Google Scholar
• Creemers, E. E.; Tijsen, A. J.; Pinto, Y. M. Circulating microRNAs: Novel Biomarkers and Extracellular Communicators in Cardiovascular Disease? Circ. Res. 2012, 110, 483–495. DOI: 10.1161/CIRCRESAHA.111.247452.
   PubMed Web of Science ®Google Scholar
• Cortez, M. A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A. K.; Calin, G. A. MicroRNAs in Body Fluids–the Mix of Hormones and Biomarkers. Nat. Rev. Clin. Oncol. 2011, 8, 467–477. DOI: 10.1038/nrclinonc.2011.76.
   PubMed Web of Science ®Google Scholar
• Deng, H.; Lv, L.; Li, Y.; Zhang, C.; Meng, F.; Pu, Y.; Xiao, J.; Qian, L.; Zhao, W.; Liu, Q.; et al. miR-193a-3p Regulates the Multi-Drug Resistance of Bladder Cancer by Targeting the LOXL4 Gene and the Oxidative Stress Pathway. Mol. Cancer. 2014, 13, 234. DOI: 10.1186/1476-4598-13-234.
   PubMed Web of Science ®Google Scholar
• Liyanage, T.; Masterson, A. N.; Oyem, H. H.; Kaimakliotis, H.; Nguyen, H.; Sardar, R. Plasmoelectronic-Based Ultrasensitive Assay of Tumor Suppressor microRNAs Directly in Patient Plasma: Design of Highly Specific Early Cancer Diagnostic Technology. Anal. Chem. 2019, 91, 1894–1903. DOI: 10.1021/acs.analchem.8b03768.
   PubMed Web of Science ®Google Scholar
• Usuba, W.; Urabe, F.; Yamamoto, Y.; Matsuzaki, J.; Sasaki, H.; Ichikawa, M.; Takizawa, S.; Aoki, Y.; Niida, S.; Kato, K.; et al. Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer. Cancer Sci. 2019, 110, 408–419. DOI: 10.1111/cas.13856.
   PubMed Web of Science ®Google Scholar
• Davalos, V.; Esteller, M. Cancer Epigenetics in Clinical Practice. CA. Cancer J. Clin. 2023, 73, 376–424. DOI: 10.3322/caac.21765.
   PubMed Web of Science ®Google Scholar
• Iacobuzio-Donahue, C. A. Epigenetic Changes in Cancer. Annu. Rev. Pathol. 2009, 4, 229–249. DOI: 10.1146/annurev.pathol.3.121806.151442.
   PubMed Web of Science ®Google Scholar
• Michalak, E. M.; Burr, M. L.; Bannister, A. J.; Dawson, M. A. The Roles of DNA, RNA and Histone Methylation in Ageing and Cancer. Nat. Rev. Mol. Cell Biol. 2019, 20, 573–589. DOI: 10.1038/s41580-019-0143-1.
   PubMed Web of Science ®Google Scholar
• Reinert, T.; Modin, C.; Castano, F. M.; Lamy, P.; Wojdacz, T. K.; Hansen, L. L.; Wiuf, C.; Borre, M.; Dyrskjøt, L.; Orntoft, T. F. Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers. Clin. Cancer Res. 2011, 17, 5582–5592. DOI: 10.1158/1078-0432.CCR-10-2659.
   PubMed Web of Science ®Google Scholar
• Schübeler, D. Function and Information Content of DNA Methylation. Nature. 2015, 517, 321–326. DOI: 10.1038/nature14192.
   PubMed Web of Science ®Google Scholar
• Hentschel, A. E.; Beijert, I. J.; Bosschieter, J.; Kauer, P. C.; Vis, A. N.; Lissenberg-Witte, B. I.; van Moorselaar, R. J. A.; Steenbergen, R. D. M.; Nieuwenhuijzen, J. A. Bladder Cancer Detection in Urine Using DNA Methylation Markers: A Technical and Prospective Preclinical Validation. Clin. Epigen. 2022, 14, 19. DOI: 10.1186/s13148-022-01240-8.
   PubMed Web of Science ®Google Scholar
• Yu, Y.; Cao, H.; Zhang, M.; Shi, F.; Wang, R.; Liu, X. Prognostic Value of DNA Methylation for Bladder Cancer. Clin. Chim. Acta. 2018, 484, 207–212. DOI: 10.1016/j.cca.2018.05.056.
   PubMed Web of Science ®Google Scholar
• Chan, M. W.; Chan, L. W.; Tang, N. L.; Tong, J. H.; Lo, K. W.; Lee, T. L.; Cheung, H. Y.; Wong, W. S.; Chan, P. S.; Lai, F. M.; To, K. F. Hypermethylation of Multiple Genes in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients. Clin. Cancer Res. 2002, 8, 464–470.
   PubMed Web of Science ®Google Scholar
• Shin, Y.; Perera, A. P.; Kee, J. S.; Song, J.; Fang, Q.; Lo, G.-Q.; Park, M. K. Label-Free Methylation Specific Sensor Based on Silicon Microring Resonators for Detection and Quantification of DNA Methylation Biomarkers in Bladder Cancer. Sens. Actuators, B. 2013, 177, 404–411. DOI: 10.1016/j.snb.2012.11.058.
   Web of Science ®Google Scholar
• Pursey, J. P.; Chen, Y.; Stulz, E.; Park, M. K.; Kongsuphol, P. Microfluidic Electrochemical Multiplex Detection of Bladder Cancer DNA Markers. Sens. Actuators, B. 2017, 251, 34–39. DOI: 10.1016/j.snb.2017.05.006.
   Web of Science ®Google Scholar
• Ruan, W.; Chen, X.; Huang, M.; Wang, H.; Chen, J.; Liang, Z.; Zhang, J.; Yu, Y.; Chen, S.; Xu, S.; et al. A Urine-Based DNA Methylation Assay to Facilitate Early Detection and Risk Stratification of Bladder Cancer. Clin. Epigenetics. 2021, 13, 91. DOI: 10.1186/s13148-021-01073-x.
   PubMed Web of Science ®Google Scholar
• Piatti, P.; Chew, Y. C.; Suwoto, M.; Yamada, T.; Jara, B.; Jia, X.-Y.; Guo, W.; Ghodoussipour, S.; Daneshmand, S.; Ahmadi, H.; et al. Clinical Evaluation of Bladder CARE, A New Epigenetic Test for Bladder Cancer Detection in Urine Samples. Clin. Epigen. 2021, 13, 84. DOI: 10.1186/s13148-021-01029-1.
   PubMed Web of Science ®Google Scholar
• Fang, Q.; Zhang, X.; Nie, Q.; Hu, J.; Zhou, S.; Wang, C. Improved Urine DNA Methylation Panel for Early Bladder Cancer Detection. BMC Cancer. 2022, 22, 237. DOI: 10.1186/s12885-022-09268-y.
   PubMed Web of Science ®Google Scholar
• Dai, X.; Ren, T.; Zhang, Y.; Nan, N. Methylation Multiplicity and Its Clinical Values in Cancer. Expert Rev. Mol. Med. 2021, 23, e2. DOI: 10.1017/erm.2021.4.
   PubMed Web of Science ®Google Scholar
• Drayton, R. M.; Dudziec, E.; Peter, S.; Bertz, S.; Hartmann, A.; Bryant, H. E.; Catto, J. W. Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11. Clin. Cancer Res. 2014, 20, 1990–2000. DOI: 10.1158/1078-0432.CCR-13-2805.
   PubMed Web of Science ®Google Scholar
• Li, F.; Zheng, Z.; Chen, W.; Li, D.; Zhang, H.; Zhu, Y.; Mo, Q.; Zhao, X.; Fan, Q.; Deng, F.; et al. Regulation of Cisplatin Resistance in Bladder Cancer by Epigenetic Mechanisms. Drug Resist. Updat. 2023, 68, 100938. DOI: 10.1016/j.drup.2023.100938.
   PubMed Web of Science ®Google Scholar
• Compton, D. A.; Cleveland, D. W. NuMA is Required for the Proper Completion of Mitosis. J. Cell Biol. 1993, 120, 947–957. DOI: 10.1083/jcb.120.4.947.
   PubMed Web of Science ®Google Scholar
• Othman, H. O.; Salehnia, F.; Fakhri, N.; Hassan, R.; Hosseini, M.; Faizullah, A.; Ganjali, M. R.; Kazem Aghamir, S. M. A Highly Sensitive Fluorescent Immunosensor for Sensitive Detection of Nuclear Matrix Protein 22 as Biomarker for Early Stage Diagnosis of Bladder Cancer. RSC Adv. 2020, 10, 28865–28871. DOI: 10.1039/d0ra06191c.
   PubMed Web of Science ®Google Scholar
• Davido, T.; Getzenberg, R. H. Nuclear Matrix Proteins as Cancer Markers. J. Cell. Biochem. Suppl. 2000, 35, 136–141. DOI: 10.1002/1097-4644(2000)79:35+<136::AID-JCB1137>3.3.CO;2-5.
   Google Scholar
• Kundal, V. K.; Pandith, A. A.; Hamid, A.; Shah, A.; Kundal, R.; Wani, S. M. Role of NMP22 Bladder Check Test in Early Detection of Bladder Cancer with Recurrence. Asian Pac. J. Cancer Prev. 2010, 11, 1279–1282.
   PubMedGoogle Scholar
• Wilson, J. L., Jr.; Antoniassi, M. P.; Lopes, P. I.; Azevedo, H. Proteomic Research and Diagnosis in Bladder Cancer: State of the Art Review. Int. Braz. J. Urol. 2021, 47, 503–514. DOI: 10.1590/S1677-5538.IBJU.2021.99.02.
   PubMed Web of Science ®Google Scholar
• Chou, R.; Gore, J. L.; Buckley, D.; Fu, R.; Gustafson, K.; Griffin, J. C.; Grusing, S.; Selph, S. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-Analysis. Ann. Intern. Med. 2015, 163, 922–931. DOI: 10.7326/M15-0997.
   PubMed Web of Science ®Google Scholar
• Mahnert, B.; Tauber, S.; Kriegmair, M.; Nagel, D.; Holdenrieder, S.; Hofmann, K.; Reiter, W.; Schmeller, N.; Stieber, P. Measurements of Complement Factor H-Related Protein (BTA-TRAK Assay) and Nuclear Matrix Protein (NMP22 Assay)–Useful Diagnostic Tools in the Diagnosis of Urinary Bladder Cancer? Clin. Chem. Lab. Med. 2003, 41, 104–110. DOI: 10.1515/CCLM.2003.018.
   PubMed Web of Science ®Google Scholar
• Wu, D.; Wang, Y.; Zhang, Y.; Ma, H.; Yan, T.; Du, B.; Wei, Q. Sensitive Electrochemical Immunosensor for Detection of Nuclear Matrix Protein-22 Based on NH2-SAPO-34 Supported Pd/Co Nanoparticles. Sci. Rep. 2016, 6, 24551. DOI: 10.1038/srep24551.
   PubMed Web of Science ®Google Scholar
• Piro, B.; Reisberg, S. Recent Advances in Electrochemical Immunosensors. Sensors. 2017, 17, 794. DOI: 10.3390/s17040794.
   PubMed Web of Science ®Google Scholar
• Cheng, K.; Wan, S.; Chen, S.-Y.; Yang, J.-W.; Wang, H.-L.; Xu, C.-H.; Qiao, S.-H.; Yang, L. Nuclear Matrix Protein 22 in Bladder Cancer. Clin. Chim. Acta. 2024, 560, 119718. DOI: 10.1016/j.cca.2024.119718.
   PubMedGoogle Scholar
• Kuburich, N. A.; den Hollander, P.; Pietz, J. T.; Mani, S. A. Vimentin and Cytokeratin: Good Alone, Bad Together. Semin. Cancer Biol. 2022, 86, 816–826. DOI: 10.1016/j.semcancer.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Southgate, J.; Harnden, P.; Trejdosiewicz, L. K. Cytokeratin Expression Patterns in Normal and Malignant Urothelium: A Review of the Biological and Diagnostic Implications. Histol. Histopathol. 1999, 14, 657–664. DOI: 10.14670/HH-14.657.
   PubMed Web of Science ®Google Scholar
• Zhu, R. J.; Zhou, J.; Liang, P. Q.; Xiang, X. X.; Ran, J.; Xie, T. A.; Guo, X. G. Accuracy of Cytokeratin 19 Fragment in the Diagnosis of Bladder Cancer. Biomark. Med. 2022, 16, 197–216. DOI: 10.2217/bmm-2021-0754.
   PubMed Web of Science ®Google Scholar
• Morita, T.; Kikuchi, T.; Hashimoto, S.; Kobayashi, Y.; Tokue, A. Cytokeratin-19 Fragment (CYFRA 21-1) in Bladder Cancer. Eur. Urol. 1997, 32, 237–244. DOI: 10.1159/000480865.
   PubMed Web of Science ®Google Scholar
• Kuang, L. I.; Song, W. J.; Qing, H. M.; Yan, S.; Song, F. L. CYFRA21-1 Levels Could Be a Biomarker for Bladder Cancer: A Meta-Analysis. Genet. Mol. Res. 2015, 14, 3921–3931. DOI: 10.4238/2015.April.27.6.
   PubMed Web of Science ®Google Scholar
• Nisman, B.; Barak, V.; Shapiro, A.; Golijanin, D.; Peretz, T.; Pode, D. Evaluation of Urine CYFRA 21-1 for the Detection of Primary and Recurrent Bladder Carcinoma. Cancer. 2002, 94, 2914–2922. DOI: 10.1002/cncr.10565.
   PubMed Web of Science ®Google Scholar
• Huang, Y. L.; Chen, J.; Yan, W.; Zang, D.; Qin, Q.; Deng, A. M. Diagnostic Accuracy of Cytokeratin-19 Fragment (CYFRA 21-1) for Bladder Cancer: A Systematic Review and Meta-Analysis. Tumour Biol. 2015, 36, 3137–3145. DOI: 10.1007/s13277-015-3352-z.
   PubMed Web of Science ®Google Scholar
• Lei, Q.; Zhao, L.; Ye, S.; Sun, Y.; Xie, F.; Zhang, H.; Zhou, F.; Wu, S. Rapid and Quantitative Detection of Urinary Cyfra21-1 Using Fluorescent Nanosphere-Based Immunochromatographic Test Strip for Diagnosis and Prognostic Monitoring of Bladder Cancer. Artif. Cells. Nanomed. Biotechnol. 2019, 47, 4266–4272. DOI: 10.1080/21691401.2019.1687491.
   PubMed Web of Science ®Google Scholar
• Shi, J. J.; Chen, Z. C.; Zhao, C. Q.; Shen, M. Q.; Li, H.; Zhang, S. S.; Zhang, Z. Photoelectrochemical Biosensing Platforms for Tumor Marker Detection. Coord. Chem. Rev. 2022, 469, 214675. DOI: 10.1016/j.ccr.2022.214675.
   Web of Science ®Google Scholar
• Zhang, S.; Wang, C.; Wu, T.; Fan, D.; Hu, L.; Wang, H.; Wei, Q.; Wu, D. A Sandwiched Photoelectrochemical Biosensing Platform for Detecting Cytokeratin-19 Fragments Based on Ag2S-Sensitized BiOI/Bi2S3 Heterostructure Amplified by Sulfur and Nitrogen co-Doped Carbon Quantum Dots. Biosens. Bioelectron. 2022, 196, 113703. DOI: 10.1016/j.bios.2021.113703.
   PubMed Web of Science ®Google Scholar
• Chen, G.; Qin, Y.; Jiao, L.; Huang, J.; Wu, Y.; Hu, L.; Gu, W.; Xu, D.; Zhu, C. Nanozyme-Activated Synergistic Amplification for Ultrasensitive Photoelectrochemical Immunoassay. Anal. Chem. 2021, 93, 6881–6888. DOI: 10.1021/acs.analchem.1c01217.
   PubMed Web of Science ®Google Scholar
• Zhang, J. H.; Xue, X. D.; Du, Y. Z.; Zhao, J. X.; Ma, H. M.; Ren, X.; Wei, Q.; Ju, H. X. Antigen-Down Pec Immunosensor for CYFRA21-1 Detection Based on Photocurrent Polarity Switching Strategy. Anal. Chem. 2022, 94, 12368–12373. DOI: 10.1021/acs.analchem.2c01478.
   PubMed Web of Science ®Google Scholar
• Gumbiner, B. M. Cell Adhesion: The Molecular Basis of Tissue Architecture and Morphogenesis. Cell. 1996, 84, 345–357. DOI: 10.1016/s0092-8674(00)81279-9.
   PubMed Web of Science ®Google Scholar
• Bryan, R. T. Cell Adhesion and Urothelial Bladder Cancer: The Role of Cadherin Switching and Related Phenomena. Phil. Trans. R Soc. B 2015, 370, 20140042. DOI: 10.1098/rstb.2014.0042.
   PubMed Web of Science ®Google Scholar
• Martins-Lima, C.; Miranda-Gonçalves, V.; Lobo, J.; Constâncio, V.; Leite-Silva, P.; Guimarães-Teixeira, C.; Monteiro-Reis, S.; Sequeira, J. P.; Cantante, M.; Gonçalves, C. S.; et al. Cadherin Switches during Epithelial-Mesenchymal Transition: CDH4/RCAD Downregulation Reduces Bladder Cancer Progression. Cell. Oncol. (Dordr). 2022, 45, 135–149. DOI: 10.1007/s13402-021-00657-2.
   PubMed Web of Science ®Google Scholar
• Griffiths, T. R.; Brotherick, I.; Bishop, R. I.; White, M. D.; McKenna, D. M.; Horne, C. H.; Shenton, B. K.; Neal, D. E.; Mellon, J. K. Cell Adhesion Molecules in Bladder Cancer: Soluble Serum E-Cadherin Correlates with Predictors of Recurrence. Br. J. Cancer. 1996, 74, 579–584. DOI: 10.1038/bjc.1996.404.
   PubMed Web of Science ®Google Scholar
• Inoue, K.; Kamada, M.; Slaton, J. W.; Fukata, S.; Yoshikawa, C.; Tamboli, P.; Dinney, C. P.; Shuin, T. The Prognostic Value of Angiogenesis and Metastasis-Related Genes for Progression of Transitional Cell Carcinoma of the Renal Pelvis and Ureter. Clin. Cancer Res. 2002, 8, 1863–1870.
   PubMed Web of Science ®Google Scholar
• Muñoz-San Martín, C.; Pedrero, M.; de Villena, F. J. M.; Garranzo-Asensio, M.; Rodríguez, N.; Domínguez, G.; Barderas, R.; Campuzano, S.; Pingarrón, J. M. Disposable Amperometric Immunosensor for the Determination of the E-Cadherin Tumor Suppressor Protein in Cancer Cells and Human Tissues. Electroanalysis. 2019, 31, 309–317. DOI: 10.1002/elan.201800645.
   Web of Science ®Google Scholar
• Hautmann, S. H.; Lokeshwar, V. B.; Schroeder, G. L.; Civantos, F.; Duncan, R. C.; Gnann, R.; Friedrich, M. G.; Soloway, M. S. Elevated Tissue Expression of Hyaluronic Acid and Hyaluronidase Validates the HA-HAase Urine Test for Bladder Cancer. J. Urol. 2001, 165, 2068–2074. DOI: 10.1016/S0022-5347(05)66296-9.
   PubMed Web of Science ®Google Scholar
• Kramer, M. W.; Golshani, R.; Merseburger, A. S.; Knapp, J.; Garcia, A.; Hennenlotter, J.; Duncan, R. C.; Soloway, M. S.; Jorda, M.; Kuczyk, M. A.; et al. HYAL-1 Hyaluronidase: A Potential Prognostic Indicator for Progression to Muscle Invasion and Recurrence in Bladder Cancer. Eur. Urol. 2010, 57, 86–93. DOI: 10.1016/j.eururo.2009.03.057.
   PubMed Web of Science ®Google Scholar
• Morera, D. S.; Hennig, M. S.; Talukder, A.; Lokeshwar, S. D.; Wang, J.; Garcia-Roig, M.; Ortiz, N.; Yates, T. J.; Lopez, L. E.; Kallifatidis, G.; et al. Hyaluronic Acid Family in Bladder Cancer: Potential Prognostic Biomarkers and Therapeutic Targets. Br. J. Cancer. 2017, 117, 1507–1517. DOI: 10.1038/bjc.2017.318.
   PubMed Web of Science ®Google Scholar
• Hautmann, S.; Toma, M.; Lorenzo Gomez, M. F.; Friedrich, M. G.; Jaekel, T.; Michl, U.; Schroeder, G. L.; Huland, H.; Juenemann, K. P.; Lokeshwar, V. B. Immunocyt and the HA-HAase Urine Tests for the Detection of Bladder Cancer: A Side-by-Side Comparison. Eur. Urol. 2004, 46, 466–471. DOI: 10.1016/j.eururo.2004.06.006.
   PubMed Web of Science ®Google Scholar
• Lokeshwar, V. B.; Obek, C.; Pham, H. T.; Wei, D.; Young, M. J.; Duncan, R. C.; Soloway, M. S.; Block, N. L. Urinary Hyaluronic Acid and Hyaluronidase: Markers for Bladder Cancer Detection and Evaluation of Grade. J. Urol. 2000, 163, 348–356. DOI: 10.1016/s0022-5347(05)68050-0.
   PubMed Web of Science ®Google Scholar
• Mehta, A.; Shapiro, M. D. Apolipoproteins in Vascular Biology and Atherosclerotic Disease. Nat. Rev. Cardiol. 2022, 19, 168–179. DOI: 10.1038/s41569-021-00613-5.
   PubMed Web of Science ®Google Scholar
• Chen, Y. T.; Chen, C. L.; Chen, H. W.; Chung, T.; Wu, C. C.; Chen, C. D.; Hsu, C. W.; Chen, M. C.; Tsui, K. H.; Chang, P. L.; et al. Discovery of Novel Bladder Cancer Biomarkers by Comparative Urine Proteomics Using iTRAQ Technology. J. Proteome Res. 2010, 9, 5803–5815. DOI: 10.1021/pr100576x.
   PubMed Web of Science ®Google Scholar
• Urquidi, V.; Goodison, S.; Ross, S.; Chang, M.; Dai, Y.; Rosser, C. J. Diagnostic Potential of Urinary α1-Antitrypsin and Apolipoprotein E in the Detection of Bladder Cancer. J. Urol. 2012, 188, 2377–2383. DOI: 10.1016/j.juro.2012.07.094.
   PubMed Web of Science ®Google Scholar
• Su, S.; Sun, Q.; Gu, X. D.; Xu, Y. Q.; Shen, J. L.; Zhu, D.; Chao, J.; Fan, C. H.; Wang, L. H. Two-Dimensional Nanomaterials for Biosensing Applications. Trac-Trends Anal. Chem. 2019, 119.115610.DOI10.1016/j.trac.2019.07.021
   Web of Science ®Google Scholar
• Sharifuzzaman, M.; Barman, S. C.; Zahed, M. A.; Sharma, S.; Yoon, H.; Nah, J. S.; Kim, H.; Park, J. Y. An Electrodeposited MXene-Ti(3)C(2)T(x) Nanosheets Functionalized by Task-Specific Ionic Liquid for Simultaneous and Multiplexed Detection of Bladder Cancer Biomarkers. Small. 2020, 16, e2002517. DOI: 10.1002/smll.202002517.
   Web of Science ®Google Scholar
• Chen, H.-C.; Chen, Y.-T.; Tsai, R.-Y.; Chen, M.-C.; Chen, S.-L.; Xiao, M.-C.; Chen, C.-L.; Hua, M.-Y. A Sensitive and Selective Magnetic Graphene Composite-Modified Polycrystalline-Silicon Nanowire Field-Effect Transistor for Bladder Cancer Diagnosis. Biosens. Bioelectron. 2015, 66, 198–207. DOI: 10.1016/j.bios.2014.11.019.
   PubMed Web of Science ®Google Scholar
• de Almeida, L. G. N.; Thode, H.; Eslambolchi, Y.; Chopra, S.; Young, D.; Gill, S.; Devel, L.; Dufour, A. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol. Rev. 2022, 74, 712–768. DOI: 10.1124/pharmrev.121.000349.
   PubMed Web of Science ®Google Scholar
• Szarvas, T.; Vom Dorp, F.; Ergün, S.; Rübben, H. Matrix Metalloproteinases and Their Clinical Relevance in Urinary Bladder Cancer. Nat. Rev. Urol. 2011, 8, 241–254. DOI: 10.1038/nrurol.2011.44.
   PubMed Web of Science ®Google Scholar
• Fouad, H.; Salem, H.; Ellakwa, D. E.; Abdel-Hamid, M. MMP-2 and MMP-9 as Prognostic Markers for the Early Detection of Urinary Bladder Cancer. J. Biochem. Mol. Toxicol. 2019, 33, e22275. DOI: 10.1002/jbt.22275.
   PubMed Web of Science ®Google Scholar
• Kubik, A.; das Virgens, I. P. A.; Szabó, A.; Váradi, M.; Csizmarik, A.; Keszthelyi, A.; Majoros, A.; Fehérvári, P.; Hegyi, P.; Ács, N.; et al. Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis. Int. J. Mol. Sci. 2023, 24, 7859. DOI: 10.3390/ijms24097859.
   PubMed Web of Science ®Google Scholar
• Kowalczyk, A.; Nisiewicz, M. K.; Bamburowicz-Klimkowska, M.; Kasprzak, A.; Ruzycka-Ayoush, M.; Koszytkowska-Stawińska, M.; Nowicka, A. M. Effective Voltammetric Tool for Simultaneous Detection of MMP-1, MMP-2, and MMP-9: Important Non-Small Cell Lung Cancer Biomarkers. Biosens. Bioelectron. 2023, 229, 115212. DOI: 10.1016/j.bios.2023.115212.
   PubMed Web of Science ®Google Scholar
• Tell, G.; Quadrifoglio, F.; Tiribelli, C.; Kelley, M. R. The Many Functions of APE1/Ref-1: Not Only a DNA Repair Enzyme. Antioxid. Redox Signal. 2009, 11, 601–620. DOI: 10.1089/ars.2008.2194.
   PubMed Web of Science ®Google Scholar
• Choi, S.; Shin, J. H.; Lee, Y. R.; Joo, H. K.; Song, K. H.; Na, Y. G.; Chang, S. J.; Lim, J. S.; Jeon, B. H. Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker. Dis. Markers. 2016, 2016, 7276502–7276508. DOI: 10.1155/2016/7276502.
   PubMed Web of Science ®Google Scholar
• Wang, X.; Meng, J.; Zhang, H.; Mou, J.; Xiong, J.; Wang, H.; Su, X.; Zhang, Y. Electrochemical Biosensor Based on Bipedal DNA Walker for Highly Sensitive Amplification Detection of Apurinic/Apyrimidinic Endonuclease 1. Sens. Actuators, B. 2023, 381, 133425. DOI: 10.1016/j.snb.2023.133425.
   Web of Science ®Google Scholar
• Li, G.; Li, J.; Li, Q. Biodegradable MnO2 Nanosheet Mediated Hybridization Chain Reaction for Imaging of Human Apurinic/Apyrimidinic Endonuclease 1 Activity in Living Cells. Nanoscale. 2019, 11, 20456–20460. DOI: 10.1039/c9nr06436b.
   PubMed Web of Science ®Google Scholar
• Kedmi, R.; Peer, D. Zooming in on Selectins in Cancer. Sci. Transl. Med. 2016, 8, 345fs11. DOI: 10.1126/scitranslmed.aag1802.
   PubMed Web of Science ®Google Scholar
• Choudhary, D.; Hegde, P.; Voznesensky, O.; Choudhary, S.; Kopsiaftis, S.; Claffey, K. P.; Pilbeam, C. C.; Taylor, J. A. 3rd, Increased Expression of L-Selectin (CD62L) in High-Grade Urothelial Carcinoma: A Potential Marker for Metastatic Disease. Urol. Oncol. 2015, 33, 387.e17-27–387.e27. DOI: 10.1016/j.urolonc.2014.12.009.
   PubMed Web of Science ®Google Scholar
• Phadke, G. S.; Satterwhite-Warden, J. E.; Choudhary, D.; Taylor, J. A.; Rusling, J. F. A Novel and Accurate Microfluidic Assay of CD62L in Bladder Cancer Serum Samples. Analyst. 2018, 143, 5505–5511. DOI: 10.1039/c8an01463a.
   PubMed Web of Science ®Google Scholar
• Zhang, Z.; Pang, S. T.; Kasper, K. A.; Luan, C.; Wondergem, B.; Lin, F.; Chuang, C. K.; Teh, B. T.; Yang, X. J. FXYD3: A Promising Biomarker for Urothelial Carcinoma. Biomark. Insights. 2011, 6, 17–26. DOI: 10.4137/BMI.S6487.
   PubMedGoogle Scholar
• Zhang, D.; Ding, C.-P.; Zheng, X.-Y.; Ye, J.-Z.; Chen, Z.-H.; Li, J.-H.; Yan, Z.-J.; Jiang, J.-H.; Huang, Y.-J. Ultrasensitive and Accurate Diagnosis of Urothelial Cancer by Plasmonic AuNRs-Enhanced Fluorescence of near-Infrared Ag2S Quantum Dots. Rare Met. 2022, 41, 3828–3838. DOI: 10.1007/s12598-022-02074-2.
   Web of Science ®Google Scholar
• Hsu, Y.-P.; Yang, H.-W.; Li, N.-S.; Chen, Y.-T.; Pang, H.-H.; Pang, S.-T. Instrument-Free Detection of FXYD3 Using Vial-Based Immunosensor for Earlier and Faster Urothelial Carcinoma Diagnosis. ACS Sens. 2020, 5, 928–935. DOI: 10.1021/acssensors.9b02013.
   PubMed Web of Science ®Google Scholar
• Altieri, D. C. Survivin, Cancer Networks and Pathway-Directed Drug Discovery. Nat. Rev. Cancer. 2008, 8, 61–70. DOI: 10.1038/nrc2293.
   PubMed Web of Science ®Google Scholar
• Konopka, K.; Spain, C.; Yen, A.; Overlid, N.; Gebremedhin, S.; Düzgüneş, N. Correlation between the Levels of Survivin and Survivin Promoter-Driven Gene Expression in Cancer and Non-Cancer Cells. Cell. Mol. Biol. Lett. 2009, 14, 70–89. DOI: 10.2478/s11658-008-0034-5.
   PubMed Web of Science ®Google Scholar
• Ferrario, A.; Rucker, N.; Wong, S.; Luna, M.; Gomer, C. J. Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response. Cancer Res. 2007, 67, 4989–4995. DOI: 10.1158/0008-5472.CAN-06-4785.
   PubMed Web of Science ®Google Scholar
• Garg, H.; Suri, P.; Gupta, J. C.; Talwar, G. P.; Dubey, S. Survivin: A Unique Target for Tumor Therapy. Cancer Cell Int. 2016, 16, 49. DOI: 10.1186/s12935-016-0326-1.
   PubMed Web of Science ®Google Scholar
• Ku, J. H.; Godoy, G.; Amiel, G. E.; Lerner, S. P. Urine Survivin as a Diagnostic Biomarker for Bladder Cancer: A Systematic Review. BJU Int. 2012, 110, 630–636. DOI: 10.1111/j.1464-410X.2011.10884.x.
   PubMed Web of Science ®Google Scholar
• Shariat, S. F.; Ashfaq, R.; Karakiewicz, P. I.; Saeedi, O.; Sagalowsky, A. I.; Lotan, Y. Survivin Expression is Associated with Bladder Cancer Presence, Stage, Progression, and Mortality. Cancer. 2007, 109, 1106–1113. DOI: 10.1002/cncr.22521.
   PubMed Web of Science ®Google Scholar
• Smith, S. D.; Wheeler, M. A.; Plescia, J.; Colberg, J. W.; Weiss, R. M.; Altieri, D. C. Urine Detection of Survivin and Diagnosis of Bladder Cancer. JAMA. 2001, 285, 324–328. DOI: 10.1001/jama.285.3.324.
   PubMed Web of Science ®Google Scholar
• Karam, J. A.; Lotan, Y.; Karakiewicz, P. I.; Ashfaq, R.; Sagalowsky, A. I.; Roehrborn, C. G.; Shariat, S. F. Use of Combined Apoptosis Biomarkers for Prediction of Bladder Cancer Recurrence and Mortality after Radical Cystectomy. Lancet Oncol. 2007, 8, 128–136. DOI: 10.1016/S1470-2045(07)70002-5.
   PubMed Web of Science ®Google Scholar
• Zhou, Z.; Zou, L.; Guan, Y.; Jiang, L.; Liu, Y.; Zhang, X.; Huang, X.; Ren, H.; Li, Z.; Niu, H.; et al. Survivin as a Potential Biomarker in the Diagnosis of Bladder Cancer: A Systematic Review and Meta-Analysis. Urol. Oncol. 2024, 42, 133–143. DOI: 10.1016/j.urolonc.2024.01.018.
   PubMed Web of Science ®Google Scholar
• Srivastava, A. K.; Singh, P. K.; Srivastava, K.; Singh, D.; Dalela, D.; Rath, S. K.; Goel, M. M.; Brahma Bhatt, M. L. Diagnostic Role of Survivin in Urinary Bladder Cancer. Asian Pac. J. Cancer Prev. 2013, 14, 81–85. DOI: 10.7314/apjcp.2013.14.1.81.
   PubMedGoogle Scholar
• Stobiecka, M.; Ratajczak, K.; Jakiela, S. Toward Early Cancer Detection: Focus on Biosensing Systems and Biosensors for an anti-Apoptotic Protein Survivin and Survivin mRNA. Biosens. Bioelectron. 2019, 137, 58–71. DOI: 10.1016/j.bios.2019.04.060.
   PubMed Web of Science ®Google Scholar
• Roake, C. M.; Artandi, S. E. Regulation of Human Telomerase in Homeostasis and Disease. Nat. Rev. Mol. Cell Biol. 2020, 21, 384–397. DOI: 10.1038/s41580-020-0234-z.
   PubMed Web of Science ®Google Scholar
• Peng, L.; Li, J.; Meng, C.; Li, J.; Tang, D.; Guan, F.; Xu, P.; Wei, T.; Li, Y. Diagnostic Value of Telomerase Activity in Patients With Bladder Cancer: A Meta-Analysis of Diagnostic Test. Front. Oncol. 2020, 10, 570127. DOI: 10.3389/fonc.2020.570127.
   PubMed Web of Science ®Google Scholar
• Zhou, X.; Xing, D. Assays for Human Telomerase Activity: Progress and Prospects. Chem. Soc. Rev. 2012, 41, 4643–4656. DOI: 10.1039/c2cs35045a.
   PubMed Web of Science ®Google Scholar
• Woo Kim, K.; Shin, Y.; Promoda Perera, A.; Liu, Q.; Sheng Kee, J.; Han, K.; Yoon, Y.-J. K.; Park, M. Label-Free, PCR-Free Chip-Based Detection of Telomerase Activity in Bladder Cancer Cells. Biosens. Bioelectron. 2013, 45, 152–157. DOI: 10.1016/j.bios.2013.02.001.
   PubMed Web of Science ®Google Scholar
• Feng, E.; Zheng, T.; Tian, Y. Dual-Mode Au Nanoprobe Based on Surface Enhancement Raman Scattering and Colorimetry for Sensitive Determination of Telomerase Activity Both in Cell Extracts and in the Urine of Patients. ACS Sens. 2018, 4, 211–217. DOI: 10.1021/acssensors.8b01244.
   PubMed Web of Science ®Google Scholar
• Guo, Y.; Liu, S.; Yang, H.; Wang, P.; Feng, Q. Proximity Binding-Triggered Multipedal DNA Walker for the Electrochemiluminescence Detection of Telomerase Activity. Anal. Chim. Acta. 2021, 1144, 68–75. DOI: 10.1016/j.aca.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Wang, G.; Wang, H.; Cao, S.; Xiang, W.; Li, T.; Yang, M. Electrochemical Determination of the Activity and Inhibition of Telomerase Based on the Interaction of DNA with Molybdate. Microchim. Acta. 2019, 186,96. DOI: 10.1007/s00604-018-3223-6.
   Web of Science ®Google Scholar
• Dai, Z.; Yang, L.; Li, Y.; Zhao, C.; Guo, J.; Gao, Z.; Song, Y.-Y. A Portable Dual-Mode Sensor Based on a TiO2 Nanotube Membrane for the Evaluation of Telomerase Activity. Chem. Commun. (Camb). 2019, 55, 10571–10574. DOI: 10.1039/c9cc05332h.
   PubMed Web of Science ®Google Scholar
• Chen, C.; Wei, M.; Liu, Y.; Xu, E.; Wei, W.; Zhang, Y.; Liu, S. Visual and Fluorometric Determination of Telomerase Activity by Using a Cationic Conjugated Polymer and Fluorescence Resonance Energy Transfer. Microchim. Acta. 2017, 184, 3453–3460. DOI: 10.1007/s00604-017-2362-5.
   Web of Science ®Google Scholar
• Ou, X.; Hong, F.; Zhang, Z.; Cheng, Y.; Zhao, Z.; Gao, P.; Lou, X.; Xia, F.; Wang, S. A Highly Sensitive and Facile Graphene Oxide-Based Nucleic Acid Probe: Label-Free Detection of Telomerase Activity in Cancer Patient’s Urine Using AIEgens. Biosens. Bioelectron. 2017, 89, 417–421. DOI: 10.1016/j.bios.2016.05.035.
   PubMed Web of Science ®Google Scholar
• Chen, C. K.; Liao, J.; Li, M. S.; Khoo, B. L. Urine Biopsy Technologies: Cancer and Beyond. Theranostics. 2020, 10, 7872–7888. DOI: 10.7150/thno.44634.
   PubMed Web of Science ®Google Scholar
• Zhu, X.; Qin, R.; Qu, K.; Wang, Z.; Zhao, X.; Xu, W. Atomic Force Microscopy-Based Assessment of Multimechanical Cellular Properties for Classification of Graded Bladder Cancer Cells and Cancer Early Diagnosis Using Machine Learning Analysis. Acta Biomater. 2023, 158, 358–373. DOI: 10.1016/j.actbio.2022.12.035.
   PubMed Web of Science ®Google Scholar
• Bryan, R. T.; Shimwell, N. J.; Wei, W.; Devall, A. J.; Pirrie, S. J.; James, N. D.; Zeegers, M. P.; Cheng, K. K.; Martin, A.; Ward, D. G. Urinary EpCAM in Urothelial Bladder Cancer Patients: Characterisation and Evaluation of Biomarker Potential. Br. J. Cancer. 2014, 110, 679–685. DOI: 10.1038/bjc.2013.744.
   PubMed Web of Science ®Google Scholar
• MacGregor, M.; Safizadeh Shirazi, H.; Chan, K. M.; Ostrikov, K.; McNicholas, K.; Jay, A.; Chong, M.; Staudacher, A. H.; Michl, T. D.; Zhalgasbaikyzy, A.; et al. Cancer Cell Detection Device for the Diagnosis of Bladder Cancer from Urine. Biosens. Bioelectron. 2021, 171, 112699. DOI: 10.1016/j.bios.2020.112699.
   PubMed Web of Science ®Google Scholar
• Khetrapal, P.; Lee, M. W. L.; Tan, W. S.; Dong, L.; de Winter, P.; Feber, A.; Kelly, J. D. The Role of Circulating Tumour Cells and Nucleic Acids in Blood for the Detection of Bladder Cancer: A Systematic Review. Cancer Treat. Rev. 2018, 66, 56–63. DOI: 10.1016/j.ctrv.2018.03.007.
   PubMed Web of Science ®Google Scholar
• Pinho, S. S.; Reis, C. A. Glycosylation in Cancer: Mechanisms and Clinical Implications. Nat. Rev. Cancer. 2015, 15, 540–555. DOI: 10.1038/nrc3982.
   PubMed Web of Science ®Google Scholar
• Ohtsubo, K.; Marth, J. D. Glycosylation in Cellular Mechanisms of Health and Disease. Cell 2006, 126, 855–867. DOI: 10.1016/j.cell.2006.08.019.
   PubMed Web of Science ®Google Scholar
• Wilczak, M.; Surman, M.; Przybyło, M. Altered Glycosylation in Progression and Management of Bladder Cancer. Molecules. 2023, 28, 3436. DOI: 10.3390/molecules28083436.
   PubMed Web of Science ®Google Scholar
• Wang, J.; Li, J.; Yan, G.; Gao, M.; Zhang, X. Preparation of a Thickness-Controlled Mg-MOFs-Based Magnetic Graphene Composite as a Novel Hydrophilic Matrix for the Effective Identification of the Glycopeptide in the Human Urine. Nanoscale. 2019, 11, 3701–3709. DOI: 10.1039/c8nr10074h.
   PubMed Web of Science ®Google Scholar
• Carapito, Â.; Roque, A. C. A.; Carvalho, F.; Pinto, J.; Guedes de Pinho, P. Exploiting Volatile Fingerprints for Bladder Cancer Diagnosis: A Scoping Review of Metabolomics and Sensor-Based Approaches. Talanta. 2024, 268, 125296. DOI: 10.1016/j.talanta.2023.125296.
   PubMed Web of Science ®Google Scholar
• Putluri, N.; Shojaie, A.; Vasu, V. T.; Vareed, S. K.; Nalluri, S.; Putluri, V.; Thangjam, G. S.; Panzitt, K.; Tallman, C. T.; Butler, C.; et al. Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. Cancer Res. 2011, 71, 7376–7386. DOI: 10.1158/0008-5472.CAN-11-1154.
   PubMed Web of Science ®Google Scholar
• Zong, C.; Xu, M. X.; Xu, L. J.; Wei, T.; Ma, X.; Zheng, X. S.; Hu, R.; Ren, B. Surface-Enhanced Raman Spectroscopy for Bioanalysis: Reliability and Challenges. Chem. Rev. 2018, 118, 4946–4980. DOI: 10.1021/acs.chemrev.7b00668.
   PubMed Web of Science ®Google Scholar
• Luo, R.; Popp, J.; Bocklitz, T. Deep Learning for Raman Spectroscopy: A Review. Analytica 2022, 3, 287–301. DOI: 10.3390/analytica3030020.
   Google Scholar
• Cui, X.; Liu, T.; Xu, X.; Zhao, Z.; Tian, Y.; Zhao, Y.; Chen, S.; Wang, Z.; Wang, Y.; Hu, D.; et al. Label-Free Detection of Multiple Genitourinary Cancers from Urine by Surface-Enhanced Raman Spectroscopy. Spectrochim. Acta, Part A. 2020, 240, 118543. DOI: 10.1016/j.saa.2020.118543.
   PubMed Web of Science ®Google Scholar
• Xiong, C.-C.; Zhu, S.-S.; Yan, D.-H.; Yao, Y.-D.; Zhang, Z.; Zhang, G.-J.; Chen, S. Rapid and Precise Detection of Cancers via Label-Free SERS and Deep Learning. Anal. Bioanal. Chem. 2023, 415, 3449–3462. DOI: 10.1007/s00216-023-04730-7.
   PubMed Web of Science ®Google Scholar
• Weber, C. M.; Cauchi, M.; Patel, M.; Bessant, C.; Turner, C.; Britton, L. E.; Willis, C. M. Evaluation of a Gas Sensor Array and Pattern Recognition for the Identification of Bladder Cancer from Urine Headspace. Analyst. 2011, 136, 359–364. DOI: 10.1039/c0an00382d.
   PubMed Web of Science ®Google Scholar
• Stone, L. Urinary VOCs as Bladder Cancer Biomarkers. Nat. Rev. Urol. 2022, 19, 256. DOI: 10.1038/s41585-022-00595-0.
   Web of Science ®Google Scholar
• Belugina, R.; Karpushchenko, E.; Sleptsov, A.; Protoshchak, V.; Legin, A.; Kirsanov, D. Developing Non-Invasive Bladder Cancer Screening Methodology through Potentiometric Multisensor Urine Analysis. Talanta. 2021, 234, 122696. DOI: 10.1016/j.talanta.2021.122696.
   PubMed Web of Science ®Google Scholar
• Jian, Y.; Zhang, N.; Liu, T.; Zhu, Y.; Wang, D.; Dong, H.; Guo, L.; Qu, D.; Jiang, X.; Du, T.; et al. Artificially Intelligent Olfaction for Fast and Noninvasive Diagnosis of Bladder Cancer from Urine. ACS Sens. 2022, 7, 1720–1731. DOI: 10.1021/acssensors.2c00467.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K.; Murakami, Y.; Shimizu, Y.; Hirayama, T.; Ishikawa, W.; Iwamura, M. Electronic Nose to Distinguish Bladder Cancer by Urinary Odour Feature: A Pilot Study. Cancer Biomark. 2020, 28, 33–39. DOI: 10.3233/CBM-190466.
   PubMed Web of Science ®Google Scholar
• Bassi, P.; Di Gianfrancesco, L.; Salmaso, L.; Ragonese, M.; Palermo, G.; Sacco, E.; Giancristofaro, R. A.; Ceccato, R.; Racioppi, M. Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study. J. Clin. Med. 2021, 10, 4984. DOI: 10.3390/jcm10214984.
   PubMed Web of Science ®Google Scholar
• Lett, L.; George, M.; Slater, R.; De Lacy Costello, B.; Ratcliffe, N.; García-Fiñana, M.; Lazarowicz, H.; Probert, C. Investigation of Urinary Volatile Organic Compounds as Novel Diagnostic and Surveillance Biomarkers of Bladder Cancer. Br. J. Cancer. 2022, 127, 329–336. DOI: 10.1038/s41416-022-01785-8.
   PubMed Web of Science ®Google Scholar
• Zhu, S.; Corsetti, S.; Wang, Q.; Li, C.; Huang, Z.; Nabi, G. Optical Sensory Arrays for the Detection of Urinary Bladder Cancer-Related Volatile Organic Compounds. J. Biophoton. 2019, 12, e201800165. DOI: 10.1002/jbio.201800165.
   PubMed Web of Science ®Google Scholar
• Doménech-Carbó, A.; Pontones, J. L.; Doménech-Casasús, C.; Ramos, D. Asymptotic Modeling of Electrochemical Signaling: Testing Zn in Urine for Non-Invasive Bladder Cancer Diagnosis. Sens. Actuators, B. 2021, 347, 130646. DOI: 10.1016/j.snb.2021.130646.
   Web of Science ®Google Scholar
• Yang, Y. B.; Wang, J. F.; Huang, W. T.; Wan, G. J.; Xia, M. M.; Chen, D.; Zhang, Y.; Wang, Y. M.; Guo, F. D.; Tan, J.; et al. Integrated Urinalysis Devices Based on Interface-Engineered Field-Effect Transistor Biosensors Incorporated With Electronic Circuits. Adv. Mater. 2022, 34, 2203224.DOI: 10.1002/adma.202203224.
   Web of Science ®Google Scholar
• Qiu, H.; Wang, J.; Zhi, Y.; Yan, B.; Huang, Y.; Li, J.; Shen, C.; Dai, L.; Fang, Q.; Shi, C.; Li, W. Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer. ACS Appl. Mater. Interf. 2023, 15, 46668–46680. DOI: 10.1021/acsami.3c09564.
   PubMed Web of Science ®Google Scholar
• Grimm, M.-O.; Bex, A.; De Santis, M.; Ljungberg, B.; Catto, J. W. F.; Rouprêt, M.; Hussain, S. A.; Bellmunt, J.; Powles, T.; Wirth, M.; Van Poppel, H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. Eur. Urol. 2019, 76, 368–380. DOI: 10.1016/j.eururo.2019.05.041.
   PubMed Web of Science ®Google Scholar
• Faraj, S. F.; Munari, E.; Guner, G.; Taube, J.; Anders, R.; Hicks, J.; Meeker, A.; Schoenberg, M.; Bivalacqua, T.; Drake, C.; Netto, G. J. Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma. Urology. 2015, 85, 703.e1-703–e6. DOI: 10.1016/j.urology.2014.10.020.
   Web of Science ®Google Scholar
• Wuethrich, A.; Rajkumar, A. R.; Shanmugasundaram, K. B.; Reza, K. K.; Dey, S.; Howard, C. B.; Sina, A. A. I.; Trau, M. Single Droplet Detection of Immune Checkpoints on a Multiplexed Electrohydrodynamic Biosensor. Analyst. 2019, 144, 6914–6921. DOI: 10.1039/c9an01450k.
   PubMed Web of Science ®Google Scholar
• Zhan, H.; Xie, H.; Zhou, Q.; Liu, Y.; Huang, W. Synthesizing a Genetic Sensor Based on CRISPR-Cas9 for Specifically Killing p53-Deficient Cancer Cells. ACS Synth. Biol. 2018, 7, 1798–1807. DOI: 10.1021/acssynbio.8b00202.
   PubMed Web of Science ®Google Scholar
• Shi, J.; Kantoff, P. W.; Wooster, R.; Farokhzad, O. C. Cancer Nanomedicine: Progress, Challenges and Opportunities. Nat. Rev. Cancer. 2017, 17, 20–37. DOI: 10.1038/nrc.2016.108.
   PubMed Web of Science ®Google Scholar
• Dosio, F.; Arpicco, S.; Stella, B.; Fattal, E. Hyaluronic Acid for Anticancer Drug and Nucleic Acid Delivery. Adv. Drug Deliv. Rev. 2016, 97, 204–236. DOI: 10.1016/j.addr.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Kaur, B.; Kumar, S.; Kaushik, B. K. Recent Advancements in Optical Biosensors for Cancer Detection. Biosens. Bioelectron. 2022, 197, 113805. DOI: 10.1016/j.bios.2021.113805.
   PubMed Web of Science ®Google Scholar
• Li, C.; Cui, Y. Z.; Ren, J. Y.; Zou, J. C.; Kuang, W.; Sun, X. Z.; Hu, X.; Yan, Y. Q.; Ling, X. M. Novel Cells-Based Electrochemical Sensor for Investigating the Interactions of Cancer Cells with Molecules and Screening Multitarget Anticancer Drugs. Anal. Chem. 2021, 93, 1480–1488. DOI: 10.1021/acs.analchem.0c03566.
   PubMed Web of Science ®Google Scholar
• Wang, Y.; Li, Z.; Lin, Q.; Wei, Y.; Wang, J.; Li, Y.; Yang, R.; Yuan, Q. Highly Sensitive Detection of Bladder Cancer-Related miRNA in Urine Using Time-Gated Luminescent Biochip. ACS Sens. 2019, 4, 2124–2130. DOI: 10.1021/acssensors.9b00927.
   PubMed Web of Science ®Google Scholar
• Masterson, A. N.; Liyanage, T.; Berman, C.; Kaimakliotis, H.; Johnson, M.; Sardar, R. A Novel Liquid Biopsy-Based Approach for Highly Specific Cancer Diagnostics: Mitigating False Responses in Assaying Patient Plasma-Derived Circulating microRNAs through Combined SERS and Plasmon-Enhanced Fluorescence Analyses. Analyst. 2020, 145, 4173–4180. DOI: 10.1039/d0an00538j.
   PubMed Web of Science ®Google Scholar
• Rong, S. Z.; Zou, L. N.; Zhu, Y.; Zhang, Z.; Liu, H. F.; Zhang, Y. C.; Zhang, H.; Gao, H. M.; Guan, H. J.; Dong, J.; et al. 2D/3D Material Amplification Strategy for Disposable Label-Free Electrochemical Immunosensor Based on rGO-TEPA@Cu-MOFs@SiO2@AgNPs Composites for NMP22 Detection. Microchem. J. 2021, 168, 106410. DOI: 10.1016/j.microc.2021.106410.
   Web of Science ®Google Scholar
• Shen, J. B. Electrochemical DNA Biosensor Based on thiolated-MWCNTs Modified Glassy Carbon Electrode for Determination of Protein and Hemoglobin in Urine at Exercise Training Levels. Int. J. Electrochem. Sci. 2021, 16, 210913. DOI: 10.20964/2021.09.12.
   Web of Science ®Google Scholar
• Wang, D. D.; Luo, L. X.; Deng, D. T.; Gong, G. A.; Qin, J. Y.; Cai, K.; Gu, Y. Y.; Mei, Y. Electrochemical Immunosensor for the Determination of Nuclear Matrix Protein 22 in Urine Using Carboxylated MWCNTs and Zeolitic Imidazolate Framework Modified with AgNPs. ACS Appl. Nano Mater. 2023, 6, 18328–18336. DOI: 10.1021/acsanm.3c03603.
   Web of Science ®Google Scholar
• Feng, Y. K.; Qu, X. Y.; Peng, Y.; Xu, X. Y.; Zhang, J.; Wang, Y.; Zhu, S.; Li, M. L.; Li, C.; Feng, N. H. Iodide-Enhanced Perovskite Nanozyme-Based Colorimetric Platform for Detection of Urinary Nuclear Matrix Protein 22. ACS Appl. Mater. Interf. 2023, 15, 27742–27749. DOI: 10.1021/acsami.3c05437.
   PubMed Web of Science ®Google Scholar
• Yang, Z. Y.; Chang, W. H.; Chiu, Y. C.; Lin, C. H. Noninvasive Detection of Bladder Cancer Markers Based on Gold Nanomushrooms and Sandwich Immunoassays. ACS Appl. Nano Mater. 2023, 6, 5557–5567. DOI: 10.1021/acsanm.2c05600.
   Web of Science ®Google Scholar
• Guan, X. L.; Lu, D.; Chen, Z. G.; Wang, Z. Y.; Zhou, G.; Fan, Y. B. Non-Invasive Detection of Bladder Cancer via Microfluidic Immunoassay of the Protein Biomarker NMP22. Anal. Methods. 2023, 15, 3275–3285. DOI: 10.1039/d3ay00664f.
   PubMed Web of Science ®Google Scholar
• Yola, M. L.; Atar, N.; Özcan, N. A Novel Electrochemical Lung Cancer Biomarker Cytokeratin 19 Fragment Antigen 21-1 Immunosensor Based on Si(3)N(4)/MoS(2) Incorporated MWCNTs and Core-Shell Type Magnetic Nanoparticles. Nanoscale. 2021, 13, 4660–4669. DOI: 10.1039/d1nr00244a.
   PubMed Web of Science ®Google Scholar
• Cheng, J.; Hu, K.; Liu, Q.; Liu, Y.; Yang, H.; Kong, J. Electrochemical Ultrasensitive Detection of CYFRA21-1 Using Ti3C2Tx-MXene as Enhancer and Covalent Organic Frameworks as Labels. Anal. Bioanal. Chem. 2021, 413, 2543–2551. DOI: 10.1007/s00216-021-03212-y.
   PubMed Web of Science ®Google Scholar
• Zhou, L.; Yang, L.; Wang, C.; Jia, H.; Xue, J.; Wei, Q.; Ju, H. Copper Doped Terbium Metal Organic Framework as Emitter for Sensitive Electrochemiluminescence Detection of CYFRA 21-1. Talanta. 2022, 238, 123047. DOI: 10.1016/j.talanta.2021.123047.
   PubMed Web of Science ®Google Scholar
• Feng, J. H.; Wu, T. T.; Cheng, Q.; Ma, H. M.; Ren, X.; Wang, X. Y.; Lee, J. Y.; Wei, Q.; Ju, H. X. A Microfluidic Cathodic Photoelectrochemical Biosensor Chip for the Targeted Detection of Cytokeratin 19 Fragments 21-1. Lab. Chip. 2021, 21, 378–384. DOI: 10.1039/d0lc01063d.
   PubMed Web of Science ®Google Scholar
• Lv, X.; Bi, M.; Xu, X.; Li, Y.; Geng, C.; Cui, B.; Fang, Y. An Ultrasensitive Ratiometric Immunosensor Based on the Ratios of Conjugated Distyrylbenzene Derivative Nanosheets with AIECL Properties and Electrochemical Signal for CYFRA21-1 Detection. Anal. Bioanal. Chem. 2022, 414, 1389–1402. DOI: 10.1007/s00216-021-03764-z.
   PubMed Web of Science ®Google Scholar
• Qu, L.; Yang, L.; Li, Y.; Ren, X.; Wang, H.; Fan, D.; Wang, X.; Wei, Q.; Ju, H. Dual-Signaling Electrochemical Ratiometric Method for Competitive Immunoassay of CYFRA21-1 Based on Urchin-like Fe3O4@PDA-Ag and Ni3Si2O5(OH)4-Au Absorbed Methylene Blue Nanotubes. ACS Appl. Mater. Interf. 2021, 13, 5795–5802. DOI: 10.1021/acsami.0c20049.
   PubMed Web of Science ®Google Scholar
• Zhang, S.; Wang, C.; Chi, H.; Hu, L.; Wang, H.; Wei, Q.; Wu, D. A Photoelectrochemical Biosensor for Detecting Cytokeratin-19 Fragments Based on CdS/Ni(OH)2 Core-Shell Nanosphere Composites Amplified by CdSe@MoSe2. Sens. Actuators, B. 2022, 360, 131643. DOI: 10.1016/j.snb.2022.131643.
   Web of Science ®Google Scholar
• Liu, S.; Dong, H.; Jiang, F.; Li, Y.; Wei, Q. Self-Powered Photoelectrochemical Biosensor with Inherent Potential for Charge Carriers Drive. Biosens. Bioelectron. 2022, 211, 114361. DOI: 10.1016/j.bios.2022.114361.
   PubMed Web of Science ®Google Scholar
• Feng, Y. G.; He, J. W.; Chen, D. N.; Jiang, L. Y.; Wang, A. J.; Bao, N.; Feng, J. J. A Sandwich-Type Electrochemical Immunosensor for CYFRA 21-1 Based on Probe-Confined in PtPd/Polydopamine/Hollow Carbon Spheres Coupled with Dendritic Au@Rh Nanocrystals. Microchim. Acta. 2022, 189,271. DOI: 10.1007/s00604-022-05372-9.
   Web of Science ®Google Scholar
• Wu, T.; Song, X.; Ren, X.; Dai, L.; Ma, H.; Wu, D.; Li, Y.; Wei, Q.; Ju, H. Catalytic Decomposition of the Hole-Derived H2O2 by AgBiS2@Ag Nanozyme to Enhance the Photocurrent of Z-Scheme BiVO4/ZnIn2S4 Photoelectrode in Microfluidic Immunosensing Platform. Anal. Chem. 2022, 94, 12127–12135. DOI: 10.1021/acs.analchem.2c02181.
   PubMed Web of Science ®Google Scholar
• Cai, K.; Pi, W.; Qin, J.; Peng, C.; Wang, D.; Gu, Y.; Mei, Y. Detection of CYFRA 21-1 in Human Serum by an Electrochemical Immunosensor Based on UiO-66-NH2@CMWCNTs and CS@AuNPs. Colloids Surf. B Biointerf. 2023, 230, 113517. DOI: 10.1016/j.colsurfb.2023.113517.
   PubMed Web of Science ®Google Scholar
• Li, X.; Zhou, Z.; Tang, Y.; Cheng Zhang, C.; Zheng, Y.; Gao, J.; Wang, Q. Modulation of Assembly and Disassembly of a New Tetraphenylethene Based Nanosensor for Highly Selective Detection of Hyaluronidase. Sens. Actuators, B. 2018, 276, 95–100. DOI: 10.1016/j.snb.2018.08.093.
   Web of Science ®Google Scholar
• Si, Y.; Li, L.; He, B.; Li, J. A Novel Surface-Enhanced Raman Scattering-Based Ratiometric Approach for Detection of Hyaluronidase in Urine. Talanta. 2020, 215, 120915. DOI: 10.1016/j.talanta.2020.120915.
   PubMed Web of Science ®Google Scholar
• Mobed, A.; Kohansal, F.; Dolati, S.; Hasanzadeh, M. A Novel Immuno-Device Based on the Specific Binding of AuNP-Supported CTAB with Biotinylated Antibody of Hyaluronic Acid toward an Early-Stage Recognition of a Biomarker: A Bioanalytical Assay in Real Samples Using Disposal Biosensor Technology. RSC Adv. 2022, 12, 28473–28488. DOI: 10.1039/d2ra04984h.
   PubMed Web of Science ®Google Scholar
• Ge, M.; Sun, J.; Chen, M.; Tian, J.; Yin, H.; Yin, J. A Hyaluronic Acid Fluorescent Hydrogel Based on Fluorescence Resonance Energy Transfer for Sensitive Detection of Hyaluronidase. Anal. Bioanal. Chem. 2020, 412, 1915–1923. DOI: 10.1007/s00216-020-02443-9.
   PubMed Web of Science ®Google Scholar
• Zhao, B.; Qi, L.; Tai, W.; Zhao, M.; Chen, X.; Yu, L.; Shi, J.; Wang, X.; Lin, J.-M.; Hu, Q. Paper-Based Flow Sensor for the Detection of Hyaluronidase via an Enzyme Hydrolysis-Induced Viscosity Change in a Polymer Solution. Anal. Chem. 2022, 94, 4643–4649. DOI: 10.1021/acs.analchem.1c04552.
   PubMed Web of Science ®Google Scholar
• Mobed, A.; Kohansal, F.; Dolati, S.; Hasanzadeh, M.; Shakouri, S. K. An Innovative Electrochemical Immuno-Platform for Monitoring Chronic Conditions Using the Biosensing of Hyaluronic Acid in Human Plasma Samples. Chemosensors. 2023, 11, 367. DOI: 10.3390/chemosensors11070367.
   Web of Science ®Google Scholar
• Li, Z.; Huang, X.; Liu, H.; Luo, F.; Qiu, B.; Lin, Z.; Chen, H. Electrochemiluminescence Biosensor for Hyaluronidase Based on the Adjustable Electrostatic Interaction between the Surface-Charge-Controllable Nanoparticles and Negatively Charged Electrode. ACS Sens. 2022, 7, 2012–2019. DOI: 10.1021/acssensors.2c00801.
   PubMedGoogle Scholar
• Hu, Q.; Su, L.; Mao, Y.; Gan, S.; Bao, Y.; Qin, D.; Wang, W.; Zhang, Y.; Niu, L. Electrochemically Induced Grafting of Ferrocenyl Polymers for Ultrasensitive Cleavage-Based Interrogation of Matrix Metalloproteinase Activity. Biosens. Bioelectron. 2021, 178, 113010. DOI: 10.1016/j.bios.2021.113010.
   PubMed Web of Science ®Google Scholar
• Nisiewicz, M. K.; Gajda, A.; Kowalczyk, A.; Cupriak, A.; Kasprzak, A.; Bamburowicz-Klimkowska, M.; Grudzinski, I. P.; Nowicka, A. M. Novel Electrogravimetric Biosensors for the Ultrasensitive Detection of Plasma Matrix Metalloproteinase-2 Considered a Potential Tumor Biomarker. Anal. Chim. Acta. 2022, 1191, 339290. DOI: 10.1016/j.aca.2021.339290.
   PubMed Web of Science ®Google Scholar
• Palomar, Q.; Xu, X.; Selegård, R.; Aili, D.; Zhang, Z. Peptide Decorated Gold Nanoparticle/Carbon Nanotube Electrochemical Sensor for Ultrasensitive Detection of Matrix Metalloproteinase-7. Sens. Actuators, B. 2020, 325, 128789. DOI: 10.1016/j.snb.2020.128789.
   Web of Science ®Google Scholar
• Xiang, L.; Cheng, W.; Zhang, J.; Li, X.; Khan, A.; Yi, Y.; Li, J. Signal-off Electrochemical Sensor for Matrix Metalloproteinase 9 Detection Based on Sacrificial FeMOF and Host-Guest Strategy. Biosens. Bioelectron. 2023, 237, 115455. DOI: 10.1016/j.bios.2023.115455.
   PubMed Web of Science ®Google Scholar
• Park, J. A.; Park, E.; Kwon, Y.; Lee, W.; Ahn, J. H.; Kim, T.-H.; Jang, M.; Min, J.; Kim, Y.; Lee, T. Synthesis of Au-Decorated Boron Nitride Nanotubes and Its Application to Pretreatment-Free Electrochemical Biosensor for Matrix metalloproteinase9 in Clinical Sample. Sens. Actuators, B. 2024, 399, 134876. DOI: 10.1016/j.snb.2023.134876.
   Web of Science ®Google Scholar